Benzinga's Top #PreMarket Losers

MEI Pharma, Inc. MEIP fell 62.90% to $2.33 in pre-market trading on failed Pracinostat and azacitidine Phase II study. Vertex Pharmaceuticals Incorporated VRTX shares declined 9.16% to $119.00 in pre-market trading after the company reported data from a 12-week Phase 2 study evaluating VX-661 in combination with ivacaftor. Gilead Sciences Inc. GILD shares dropped 2.85% to $99.38 in pre-market after rising 0.84% on Friday. Carnival Corporation CCL shares fell 1.98% to $45.95 in pre-market trading. Deutsche Bank downgraded Carnival from Buy to Hold. Biogen Idec Inc. BIIB slipped 1.47% to $469.00 in pre-market trading. The company reported that effective today, Biogen Idec will be known simply as Biogen. Stifel Nicolaus downgraded Biogen from Buy to Hold.